CD14

Across TCGA pan-cancer cohorts, CD14 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CD14 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CD14 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CD14 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

COAD, PDAC, and UCEC are the cancer types where CD14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.920	1.000	.014	54	view →
PDAC	DFS	Median	All	0.215	0.426	.010	14	view →
UCEC	DFS	Median	All	0.840	0.970	.005	8	view →
CCRCC	OS	Tertile	III,IV	0.553	0.854	.026	8	view →
LUAD	OS	Quartile	III,IV	0.180	0.673	.005	6	view →
GBM	OS	Median	All	0.280	0.529	.016	6	view →
HNSC	DFS	Quartile	III,IV	0.985	0.484	.036	2	view →
LSCC	OS	Median	All	0.767	1.000	.015	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CD14–COAD (DFS)

Open the COAD breakdown →